Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients.
Official title: A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients
Key Details
Gender
All
Age Range
2 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
4
Start Date
2020-05-13
Completion Date
2024-04-24
Last Updated
2026-05-20
Healthy Volunteers
No
Conditions
Interventions
Human T Lymphoid Progenitor (HTLP) injection
Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
Locations (1)
Unité d'Immunologie Hématologie Rhumatologie Pédiatrique (UIHR),
Paris, Île-de-France Region, France